NYSE: TMOThermo Fisher Scientific Inc Stock
$628.71+6.46 (+1.04%)
Updated Dec 7, 2021
TMO Price
$628.71
Fair Value Price
N/A
Market Cap
$252.10B
52 Week Low
$433.52
52 Week High
$666.65
P/E
28.96x
P/B
6.51x
P/S
5.78x
PEG
63.65x
Dividend Yield
0.16%
Revenue
$39.06B
Earnings
$8.57B
Gross Margin
51.1%
Operating Margin
26.59%
Profit Margin
21.9%
Debt to Equity
0.9
Operating Cash Flow
$10B
Beta
0.82
Next Earnings
Jan 31, 2022
Ex-Dividend
Dec 14, 2021
Next Dividend
Jan 14, 2022
Zen Score
High
Medium
Low
50
Industry average
Reasons for this score
TMO ($628.71) is trading above its intrinsic value of $481.17, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
TMO is good value based on its earnings relative to its share price (28.96x), compared to the US market average 37.78x)
Valuation
TMO is good value based on its earnings relative to its share price (28.96x), compared to the US Diagnostics & Research industry average (37.34x)
Valuation
TMO News
Valuation
TMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
28.96x
Industry
37.34x
Market
37.78x
TMO is good value based on its earnings relative to its share price (28.96x), compared to the US market average 37.78x)
Valuation
TMO is good value based on its earnings relative to its share price (28.96x), compared to the US Diagnostics & Research industry average (37.34x)
Valuation
TMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.51x
Industry
6.11x
TMO is poor value based on its book value relative to its share price (6.51x), compared to the US Diagnostics & Research industry average (6.11x)
Valuation
TMO price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMO is poor value relative to its rate of earnings growth, measured by PEG ratio (63.65x)
Valuation
TMO's financial health
Profit margin
Revenue
$9.3B
Net Income
$1.9B
Profit Margin
20.4%
TMO's Earnings (EBIT) of $10.39B can safely cover interest payments on company debt ($21.71B)
Financials
TMO's profit margin has increased (+4.8%) in the last year from (17.1%) to (21.9%)
Financials
Assets to liabilities
Assets
$73.6B
Liabilities
$34.9B
Debt to equity
0.56
TMO's short-term assets ($24.72B) exceed its short-term liabilities ($7.75B)
Financials
TMO's long-term liabilities ($27.14B) exceed its short-term assets ($24.72B)
Financials
TMO's debt relative to shareholder equity (0.9) has decreased or remained constant compared to 5 years ago (1.22)
Financials
TMO's debt to equity ratio (0.9) is considered high
Financials
Cash flow
Operating
$2.7B
Investing
-$616.0M
Financing
$3.0B
TMO's operating cash flow ($10.19B) is sufficient to service the company's debt ($21.71B)
Financials
Thermo Fisher Scientific Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.